Aprea Therapeutics, Inc.
Every calculator, already run for APRE
Open the full toolkit →You have the numbers on APRE. Get the argument.
A written report on which of these readings actually decide the outcome for Aprea Therapeutics, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
3 analysts covering APREAnalyst Price Target Disagreement for Aprea Therapeutics, Inc.
Wall Street's bull case implies +557% from the current price; the bear case implies +58%. A 499% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for APRE
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Aprea Therapeutics, Inc.
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.
APRE — frequently asked
Is APRE a buy right now?
Wall Street's consensus rating on Aprea Therapeutics, Inc. is none across 3 analysts, with a mean price target of $3.73 (+391% vs. the current $0.76). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
What is the analyst price target disagreement for Aprea Therapeutics, Inc.?
Analysts covering Aprea Therapeutics, Inc. (APRE) range from a bear-case target of $1.20 to a bull-case high of $5.00, with a mean consensus target of $3.73 across 3 analysts. The spread of $3.80 (499% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Aprea Therapeutics, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Aprea Therapeutics, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full APRE research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Aprea Therapeutics, Inc., in minutes. 3 free reports included with every account — no credit card required.